Karyopharm Therapeutics (NASDAQ:KPTI) Cut to “Hold” at StockNews.com

StockNews.com cut shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a buy rating to a hold rating in a research note issued to investors on Friday.

KPTI has been the topic of a number of other reports. Robert W. Baird lowered their price target on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a research report on Friday, November 1st. Piper Sandler lifted their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Karyopharm Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Stock Performance

Shares of NASDAQ KPTI opened at $0.85 on Friday. The stock has a 50 day moving average price of $0.83 and a 200 day moving average price of $0.89. The stock has a market capitalization of $105.90 million, a PE ratio of -0.74 and a beta of 0.16. Karyopharm Therapeutics has a 52 week low of $0.62 and a 52 week high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.01. The business had revenue of $38.78 million during the quarter, compared to the consensus estimate of $37.86 million. During the same quarter in the prior year, the company earned ($0.30) EPS. As a group, research analysts forecast that Karyopharm Therapeutics will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several hedge funds have recently bought and sold shares of KPTI. Point72 DIFC Ltd acquired a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Karyopharm Therapeutics in the 2nd quarter valued at $143,000. Acadian Asset Management LLC bought a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at $167,000. Exchange Traded Concepts LLC raised its holdings in shares of Karyopharm Therapeutics by 34.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after buying an additional 56,613 shares in the last quarter. Finally, FMR LLC lifted its position in shares of Karyopharm Therapeutics by 26.1% during the 3rd quarter. FMR LLC now owns 369,723 shares of the company’s stock worth $307,000 after buying an additional 76,510 shares during the last quarter. 66.44% of the stock is owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).